Advertisement

Organisation › Details
Novartis (Group)
Novartis provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, eye care and cost-saving generic pharmaceuticals. Novartis is the only global company with leading positions in these areas. In 2015, the Group achieved net sales of USD 49.4 billion, while R&D throughout the Group amounted to approximately USD 8.9 billion (USD 8.7 billion excluding impairment and amortization charges). Novartis Group companies employ approximately 119,000 full-time-equivalent associates. Novartis products are available in more than 180 countries around the world. *
![]() |
Start | 1996-12-20 merged |
Predecessor | Ciba-Geigy (Group) | |
![]() |
Industry | CHEMICALS |
![]() |
Person | Narasimhan, Vasant (Vas) (Novartis 201408– Global Head Developm Novartis Pharma before Global Head Developm Vaccines |
Person 2 | Reinhardt, Jörg (Novartis 201308– Board Chairman before Bayer 201008– CEO Bayer HealthCare AG before Novartis COO) | |
![]() |
Region | Basel BS |
Country | Switzerland | |
City | 4002 Basel BS | |
Tel | +41-61-324-2200 | |
Address record changed: 2020-12-02 | ||
Basic data | Employees | J: more than 100,0 (2019-12-31) |
Currency | USD | |
Annual sales | 47,498,000,000 (sales, net, continued operations, consolidated (2019) 2019-12-31) | |
Profit | 7,147,000,000 (2019-12-31) | |
Cash | 9,485,000,000 (2017-12-31) | |
* Document for �About Section�: Novartis AG. (1/27/16). "Press Release: Novartis Delivered Strong Sales Growth and Core Margin Expansion (cc[1]) in 2015, Announces Plans to Accelerate Growth at Alcon, Streamline Group Operations". Basel. | ||
Record changed: 2020-12-25 |
Advertisement

More documents for Novartis (Group)
- [1] Novartis AG. (1/11/21). "Press Release: Novartis Expands Oncology Pipeline with In-licensing of Tislelizumab from BeiGene". Basel....
- [2] Cadent Therapeutics. (12/17/20). "Press Release: Cadent Therapeutics Enters Agreement to Be Acquired by Novartis". Cambridge, MA....
- [3] Novartis AG. (12/17/20). "Press Release: Novartis Builds on Commitment to Addressing Need in Neuropsychiatric Disorders with Cadent Therapeutics Acquisition". Basel....
- [4] RetinAI Medical AG. (12/8/20). "Press Release: RetinAI Announces Collaboration with Novartis to Provide Artificial Intelligence Solutions in Ophthalmology". Bern....
- [5] Novartis AG. (11/19/20). "Press Release: Novartis Secures Exclusive Rights for Potential Acute Respiratory Distress Syndrome Cell Therapy". Basel....
- [6] Vedere Bio, Inc.. (10/29/20). "Press Release: Novartis Acquires Vedere Bio, a Novel Optogenetics AAV Gene Therapy Company". Cambridge, MA....
- [7] Novartis AG. (10/29/20). "Press Release: Novartis Acquires Vedere Bio, Adding Novel Optogenetic Gene Therapy Technology for Treating Blindness". Basel....
- [8] Rappta Therapeutics Oy. (10/13/20). "Press Release: Rappta Therapeutics Raises Series A Financing for the Development of Phosphatase 2A Drugs". Helsinki....
- [9] Merck KGaA. (10/6/20). "Press Release: Merck Announces Out-Licensing Agreement for Phase II-ready Anti-ADAMTS5 Nanobody for Osteoarthritis [Not intended for UK and US based media]". Darmstadt....
- [10] Numab Therapeutics AG. (9/30/20). "Press Release: Numab Therapeutics Appoints Daniel Vasella as New Chairman of the Board". Wädenswil (Zurich)....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]
Advertisement
![Picture [iito] Made Without Love 650x80px](/banner/iito-business-intelligence-20200507-650-080-summer-banner-series-made-without-love.jpg)
» top